Literature DB >> 28036281

The prognostic value of long noncoding RNA HOTTIP on clinical outcomes in breast cancer.

Yinlong Yang1, Jinxian Qian1, Youqun Xiang2, Yizuo Chen2, Jinmiao Qu2.   

Abstract

Although a few studies have assessed the prognostic value of long noncoding RNA HOTTIP in patients with malignant tumors, the relationship between HOTTIP and clinical outcome of breast cancer remains elusive. The aim of this study is to explore the prognostic significance of HOTTIP in breast cancer patients. A meta-analysis was performed to involve the eligible studies to investigate the association of HOTTIP expression level with outcome in cancer patients. Pooled hazard ratios (HRs) and 95% confidence interval (CI) of HOTTIP for cancer survival were calculated. Five relevant articles involving 460 patients with various solid carcinomas were included in this meta-analysis. For overall survival, high HOTTIP expression could significantly predict worse outcome with the pooled HR of 2.29 (95 % CI 1.72-3.03, P < 0.00001). Furthermore, Gene Expression Omnibus was performed to evaluate the association of HOTTIP expression with the prognosis in breast cancer patients. It was also found an indication that high HOTTIP expression was associated with worse survival in breast cancer patients by microarray analysis (GSE20711, GSE16446 and GSE9195). Finally, association between HOTTIP levels and clinicopathological factors and prognosis was also analyzed in an independent validation cohort including 100 breast cancer cases. HOTTIP expression was correlated with tumor size (P=0.025), lymph node status (P=0.009) and TNM stage (P=0.0001) in the breast cancer validation cohort. The Kaplan-Meier survival curves indicated that breast cancer patients with high HOTTIP expression had worse overall survival (P=0.0139) and disease-free survival (P=0.0003). Multivariate survival analysis based on the Cox proportional hazards model showed that HOTTP is considered as an independent prognostic factor in breast cancer patients. Together, our combined results suggest that high HOTTIP expression may be serving as an unfavorable prognosis predictor for breast cancer patients.

Entities:  

Keywords:  HOTTIP; breast cancer; long non-coding RNA; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28036281      PMCID: PMC5351673          DOI: 10.18632/oncotarget.14304

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Breast cancer (BC) is the most common cancer in women with 246,660 newly estimated diagnosed cases and40,450 estimated deaths in the United States in 2016 [1]. Remarkable progresses have been made during recent decades. However, BC is a highly heterogeneous disease, which is diverse in its responsiveness to treatment [2, 3]. Thus, there has been increasing interest on identifying novel prognostic biomarkers to predict its biological behavior. New biomarkers can also improve treatment design and contribute to the development of new therapeutic targets. Long noncoding RNAs (lncRNAs) are defined as RNA molecules with more than 200 nucleotides in length not translated into protein. Once considered as transcriptional noise, lncRNAs have now been shown to be involved in genome packaging, chromatin organization, dosage compensation, genomic imprinting and gene regulation [4]. Recently, emerging evidences have demonstrated the characterization of lncRNAs as a critical component in cancer biology [5, 6]. Abnormally expressed lncRNAs have either oncogenic or tumor suppressor functions during cancer initiation, development and progression [7]. Given that many lncRNAs are expressed in the way of tissue and cancer type restriction, specific lncRNAs are now likely to be translated into clinical applications for diagnosis, prognosis or predicting the response of treatment [8, 9]. The HOXA transcript at the distal tip (HOTTIP) lncRNA, located at the 5′end of the HOXA cluster, was recently functionally characterized [10]. Increased HOTTIP expression has been reported in tongue squamous cell carcinoma [11], lung cancer [12], pancreatic cancer [13], hepatocellular carcinoma [14], osteosarcoma [15], gastric cancer [16], glioma [17] and prostate cancer [18]. In these tumors, HOTTIP may serve as a potential oncogene and be an adverse prognostic factor in patients. However, little is known about the significance of HOTTIP expression and BC prognosis to date. In this study, we performed a meta-analysis to investigate the relationship between HOTTIP expression and the survival in patients with various cancers. Additionally, Gene Expression Omnibus (GEO) dataset were selected to disclose the association between the expressions of HOTTIP and BC prognosis. Furthermore, we conducted a validation set to verify the prognostic significance of HOTTIP in BC patients.

RESULTS

Meta-analysis and microarray analysis

A total of 23 studies using the above search strategy were retrieved. A flow diagram of the identification and selection of studies is shown in Figure 1. After evaluation, five studies including 460 patients were finally enrolled for further analysis [11, 14–16, 21]. The sample size ranged from 52 to 156 patients. For all studies, expression of HOTTIP was assessed by RT-PCR. These studies were all retrospective in design. Four studies evaluated patients from China, one evaluated patients from Switzerland. The types of cancers in these studies included hepatocellular cancer, tongue squamous cell carcinoma, colorectal cancer, osteosarcoma and gastric cancer. Table 1 presented the detailed parameters of the included studies. In the fixed effects model, meta-analysis of 5 studies on the prognostic value of HOTTIP expression indicated that higher expression level of HOTTIP significantly predicted worse overall survival (OS) in various solid carcinomas, with the pooled HR of 2.29 (95 % CI 1.72–3.03, P < 0.00001; Figure 2). Finally, funnel plot and Egger's test were used to evaluate the publication bias of the included studies. The shape of the funnel plot did not reveal any evidence of obvious asymmetry (Figure 3).
Figure 1

Flow diagram of the identification and selection of studies

Table 1

Characteristics of the all included studies in the meta-analysis

StudyYearCountryCancer typeNumberSampleCut-offMethodOutcomeFollow-up(months)
Quagliata2014SwitzerlandHepatocellular cancer52TissueROCqRT-PCROS≥60
Zhang2014ChinaTongue squamous cell carcinoma86TissueMedianqRT-PCROS38(range,23–60)
Ren2015ChinaColorectal cancer156TissueMedianqRT-PCROS46(range,33-65)
Li2015ChinaOsteosarcoma68TissueMedianqRT-PCROS≥60
Ye2016ChinaGastric cancer98TissueMedianqRT-PCROS≥60

ROC, receiver operating characteristic; qRT-PCR, quantitative real-time polymerase chain reaction; OS, overall survival.

Figure 2

Forest plots of studies evaluating hazard ratios of overall survival comparing high and low HOTTIP expression among patients with solid cancer

Figure 3

Funnel plot for identifying publication bias in the association between HOTTIP expression and overall survival of patients with solid tumors

ROC, receiver operating characteristic; qRT-PCR, quantitative real-time polymerase chain reaction; OS, overall survival. Given that meta-analysis identified that aberrant overexpression of HOTTIP is associated with unfavorable survival in patients with various solid cancer. There is no available report on the relationship between HOTTIP and BC. Hence, we performed Gene Expression Omnibus (GEO) dataset parameters to disclose the association between the expression of HOTTIP and prognosis of BC. Three microarray datasets (GSE20711, GSE16446, GSE9195) which included BC patients were collected from the GEO. It demonstrated that BC patients with high HOTTIP expression had worse OS (GSE20711, GSE16446) and relapse free survival (GSE9195) (Figure 4).
Figure 4

Up-regulated HOTTIP was associated with poor prognosis in breast cancer

Overall survival (OS) and relapse free survival (RFS) analysis of patients with low and high HOTTIP expression using a Kaplan-Meier curve in the GSE20711 A. GSE16446 B. and GSE9195. C. datasets. HR: hazard ratio.

Up-regulated HOTTIP was associated with poor prognosis in breast cancer

Overall survival (OS) and relapse free survival (RFS) analysis of patients with low and high HOTTIP expression using a Kaplan-Meier curve in the GSE20711 A. GSE16446 B. and GSE9195. C. datasets. HR: hazard ratio.

Correlations between HOTTIP expression and clinical characteristics in BC patients

To further validate whether the HOTTIP could predict the prognosis in BC patients, we conducted an independent validation set including 100 BC cases by the method of qRT-PCR. BC tissue samples were classified into low-expression group (n=50) and high-expression group (n=50), according to the median expression level of all BC samples. The association between HOTTIP expression levels and clinicopathological characteristics in patients with BC was showed in Table 2. Overall, high HOTTIP expression levels were positively correlated with tumor size, lymph node status and TNM stage (P=0.025, 0.009, 0.0001, respectively). However, HOTTIP expression in BC was not associated with other parameters such as age (p=0.161), menopausal status (p=0.728), grade (p=0.685), ER status (p=0.161), PR status (p=0.422), Her-2 status (p=0.135) (Table 2). These data imply that up-regulated HOTTIP correlates with BC progression.
Table 2

Correlation between HOTTIP expression and clinicopathological features in patients with breast cancer

VariablesHOTTIP expressionP value
Low(n=50)High(n=50)
Age0.161
  ≦502330
  >502720
Menopausal status0.728
  Premenopausal2532
  Postmenopausal2528
Tumor size0.025*
  ≦2cm2615
  >2cm2435
Lymph node status0.009*
  Negative3118
  Positive1932
Grade0.685
  I-II2022
  III3028
ER status0.161
  Negative2128
  Positive2922
PR0.422
  Negative2529
  Positive2521
HER-2/neu status0.135
  Negative3025
  Positive2025
Clinical stage0.0001*
  I-II4224
  III826

Association between HOTTIP expression and BC patient survival

In order to assess the prognostic value of HOTTIP expression for BC, we analyzed the prognostic value of HOTTIP expression levels in 100 BC patients using Kaplan–Meier analysis and the log-rank test. As shown in Figure 5, patients with high HOTTIP expression had worse disease-free survival (DFS) than those with low HOTTIP expression (P = 0.0003; Figure 5A). More importantly, the high HOTTIP expression group had shorter OS than the low expression group (P = 0.0139; Figure 5B). Moreover, univariate analysis of OS and DFS revealed that HOTTIP overexpression was an unfavorable prognostic factor in BC patients (OS, P=0.002; DFS, P<0.001; Table 3, 4), regardless of other clinicopathological features, such as tumor size, lymph node metastasis, TNM stage, Her-2 status. Finally, Multivariate survival analysis based on the Cox proportional hazards model showed that high HOTTIP expression had an HR of 7.121 for the OS (95% CI=1.176-43.109, P=0.033) and an HR of 4.083 for the DFS (95% CI=1.133–14.713, P=0.03). By comparison, TNM stage had an HR of 2.729 (95% CI 1.103-6.755, P=0.030) for the OS and an HR of 2.555 for the DFS (95% CI 1.219-5.353, P=0.013) (Table 3, 4). Thus, HOTTIP expression was an independent prognostic indicator for survival in BC patients.
Figure 5

Kaplan–Meier survival curves were stratified by HOTTIP expression level in breast cancer patients

Patients in high HOTTIP group showed decreased disease-free survival (DFS, A) and overall survival (OS, B), as compared with low HOTTIP group, p = 0.0003 and p = 0.0139, respectively. The p value was calculated using the log-rank test.

Table 3

Univariate and multivariate Cox regression analyses of overall survival in breast cancer patients

VariablesUnivariate analysisMultivariate analysis
HR(95%CI)P valueHR(95%CI)P value
Age(years), ≦50 versus >501.245(0.446-3.502)0.671
Menopausal status, Premenopausal versus Postmenopausal1.462(0.520-4.112)0.472
Tumor size(cm), ≦2 versus >22.411(0.856-6.791)0.096
Lymph node status, negative versus positive3.671(1.196-11.262)0.0230.821(0.147-4.587)0.822
Grade I-II versus III1.973(0.674-5.770)0.215
ER status, negative versus positive0.247(0.075-0.814)0.0220.408(0.052-3.194)0.393
RR status, negative versus positive0.190(0.051-0.708)0.0130.206(0.024-1.738)0.147
HER-2/neu status, negative versus positive5.156(1.754-15.157)0.0031.665(0.427-6.941)0.462
TNM stage, I-II versus III2.996(1.697-5.290)0.0002.729(1.103-6.755)0.030
HOTTIP expression, low versus high11.294(2.435-52.3970.0027.121(1.176-43.109)0.033
Table 4

Univariate and multivariate Cox regression analyses of disease-free survival in breast cancer patients

VariablesUnivariate analysisMultivariate analysis
HR(95%CI)P valueHR(95%CI)P value
Age(years), ≦50 versus >501.123(0.475-2.660)0.791
Menopausal status, Premenopausal versus Postmenopausal2.003(0.841-4.769)0.117
Tumor size(cm), ≦2 versus >22.776(1.159-6.649)0.0221.849(0.555-6.162)0.317
Lymph node status, negative versus positive3.473(1.417-8.515)0.0070.772(0.184-3.238)0.723
Grade I-II versus III2.837(1.127-7.146)0.0271.188(0.328-4.296)0.793
ER status, negative versus positive0.579(0.244-1.373)0.215
PR status, negative versus positive0.463(0.190-1.125)0.089
HER-2/neu status, negative versus positive4.943(1.903-12.843)0.0012.848(0.802-10.119)0.106
TNM stage, I-II versus III3.786(2.095-6.844)0.0002.555(1.219-5.353)0.013
HOTTIP expression, low versus high9.750(3.319-28.645)0.0004.083(1.133-14.713)0.03

Kaplan–Meier survival curves were stratified by HOTTIP expression level in breast cancer patients

Patients in high HOTTIP group showed decreased disease-free survival (DFS, A) and overall survival (OS, B), as compared with low HOTTIP group, p = 0.0003 and p = 0.0139, respectively. The p value was calculated using the log-rank test.

DISCUSSION

As far as it is concerned, our study is the first report data for the HOTTIP expression and prognosis in patients with BC. In this two-phase study, we systematically investigate the relationship between HOTTIP expression and the survival in patients with various cancers by a meta-analysis. Then, we analyzed the association between the HOTTIP expression and prognosis of BC in three GEO cohorts with BC patients. In the second phase, we evaluated the clinical significance of HOTTIP as a prognostic biomarker for BC patients by using a validation study. We found that HOTTIP expression is associated with the clinicopathological features and prognosis of BC. Thus, HOTTIP can function as a biomarker for malignancy and monitoring prognosis in BC clinically. Emerging evidence suggests that lncRNAs constitute critical part of tumor biology. Abnormal expression of lncRNAs in cancer marks the spectrum of cancer progression and may serve as an predictor for prognosis in patient s with cancer [9, 22, 23]. Rinn et al. have identified 231 non-coding RNAs associated with human HOX gene loci and these RNAs are spatially expressed and sequence-specific [6]. As the first HOX-associated InRNA that was characterized, HOTAIR was initially identified as a scaffold RNA which was associated with the chromatin-modifying PRC2 complex and the H3K27me3 histone mark, the latter of which is related to gene suppression. Subsequent studies showed that HOTAIR directly interacted with both the PRC2 and LSD1/REST/CoREST repressor complexes [6, 7, 24]. HOTAIR overexpression has been demonstrated in primary breast tumors and metastases. Its overexpression has been shown to alter gene expression pattern of breast epithelial cells to a patter similar to embryonic and neonatal fibroblasts, whereas its down-regulation has changed pattern of H3K27 methylation and decreased invasiveness [7]. Another study has shown that its expression may be an independent biomarker for the prediction of metastasis risk in ER positive BC patients [25]. In addition, its transcription has been shown to be induced by estrogen whereas inhibited by tamoxifen [26]. A recent study indicated its significant overexpression in the HER2-enriched subtype BC [27]. The oncogene functions and unfavorable prognostic significance of HOTAIR have been reported in multiple cancers including BC, whereas the expression and functions of other HOX-associated lncRNAs in cancer cell lines have not been extensively studied. Recently, HOTTIP has drawn increasing attention among cancer-related lncRNAs, which have been demonstrated to regulate genes by various mechanisms including epigenetic modifications, lncRNA-miRNA and lncRNA-protein interactions [10, 28, 29]. It has been confirmed that HOTTIP could directly interact with the Trithorax protein WDR5 inducing an open DNA-chromatin configuration to target WDR5/MLL complexes driving histone H3 lysine 4 trimethylation and thus regulating the transcription of 5′end HOXA locus genes [10]. Interestingly, recent studies also found that there is a positive correlation between the expression of HOTTIP and HOX genes in tumors and normal tissue [14, 30–33]. It has demonstrated that HOTTIP was involved in the cancer progression. For example, Tsang et al. reported that knockdown of HOTTIP attenuated hepatocellular carcinoma cell proliferation in vitro and markedly abrogated tumorigenicity in vivo. Furthermore, knockdown of HOTTIP also inhibited cancer cells migration and significantly abrogated lung metastasis in mouse xenograft mode [34]. A similar trend was seen in our study. We also found that that the expression of HOTTIP was positively correlated with tumor size, lymph node metastasis and clinical stage in BC. Furthermore, univariate analysis and multivariate analysis indicated that HOTTIP could be an independent prognostic factor and overexpression of HOTTIP was correlated with unfavorable survival in BC patients. Taken together, our data revealed that HOTTIP was implicated in the progress of BC and it might act as a tumor oncogene. To the best of our knowledge, it was the first report about the association of HOTTIP with the progression and prognosis of BC. However, our study still has several limitations. For one thing, it is a retrospective study, conducted on a small sample. For another, in vitro and in vivo experiments are needed to be conducted to further validate the biological effects of HOTTIP on breast cancer. The underlying mechanisms also remain unknown and deserve further research. In summary, our findings indicate that HOTTIP expression level has the potential to be an independent unfavorable prognostic indicator for BC patients. The results of this study indicated that HOTTIP may be a novel prognostic marker and a potential new target for BC therapy.

MATERIALS AND METHODS

Meta-analysis search strategy

We performed meta-analysis according to the guidelines of the Meta-analysis of Observational Studies in Epidemiology group (MOOSE) [19]. We searched online PubMed, EMBASE and ISI Web of Science from January 1st, 2011 to October1st, 2016 to identify relevant studies. Two sets of key words were used among that process, namely “HOTTIP and cancer”. A manual review of the references of relevant publications was also performed to obtain more studies.

Inclusion and exclusion criteria

Eligible studies included in this meta-analysis met the following criteria: (I) they studied the patients with any type of cancer; (II) they measured the expression of HOTTIP; and (III) they investigated the association between HOTTIP expression levels and cancer survival outcome. Articles were excluded on the basis of the following criteria: (I) review articles or letters, (II) non-English articles, (III) animal or laboratory studies. (IV) studies of nondichotomous HOTTIP expression levels, (V)absence of key information about survival outcome such as hazard ratio (HR), 95% CI and P value. When a study reporting the same patient cohort was included in several publications, only the most latest or complete study was selected. If any doubt of suitability remained after the abstract was examined, the complete manuscript was obtained.

Quality assessment

Two authors critically assessed the quality of all the studies included according to a basic standard as follows: I) clear report of study population and origin of country, II) clear definition of study design, III) clear definition of type of carcinoma, IV) clear definition of outcome assessment, V) clear definition of measurement of HOTTIP, and VI) sufficient follow-up time. Otherwise, the study was removed in order to enhance the quality of the meta-analysis.

Data extraction

Two reviewers independently extracted the required information from all eligible studies to rule out any discrepancy. The following data were extracted: first author, year of publication, country of origin, sample size, tumor type, method of testing HOTTIP and the cut-off, follow-up, HR of HOTTIP for overall survival (OS) as well as corresponding 95 % confidential interval (CI) and P value. Multivariate Cox hazard regression analysis was used in the present analysis. When HR data were not available but appropriate summary statistics or Kaplan-Meier curves were provided, we calculated HR using the described method [20]. Disagreements were resolved by discussion. All the data were subject to consensus.

Patients and tissue samples

The 100 cases of clinical specimens were collected from the First Affiliated Hospital of Wenzhou Medical University, between June 2006 and June 2009. All the patients analyzed in this study underwent resection of primary BC. All the cases were histopathologically confirmed as invasive ductal adenocarcinoma. All the resected tissue samples were immediately frozen in liquid nitrogen and stored at −80°C until RNA extraction. The clinical and pathological characteristics of each patient were also collected. All patients completed the follow-up, until 30 July 2016. Overall survival (OS) was defined as the interval between the dates of surgery and death. Disease free survival (DFS) was defined as the interval between the dates of surgery and disease recurrence and distant metastasis. All patients gave written informed consent for the collection of biomaterials. Approval for this study was received from the Ethics Committee of the host institution.

RNA extraction and quantitative real-time PCR analysis

Total RNA was extracted using TRIzol reagent (Invitrogen). After converting total RNA to cDNA in a reverse transcription (RT) reaction, qPCR were used to quantitate the mRNA expression levels. To detect HOTTIP expression, we used the SYBR Green method. The following primers were used in this study: HOTTIP were 5′-GTGGGGCCCAGACCCGC-3′ (forward) and 5′-AATGATAGGGACACATCGGGGAACT-3′ (reverse). Beta-actin, 5′-TCCTCTCCCAAGTCCACACA-3′ (forward) and 5-GCACGAAGGCTCATCATTCA-3′(reverse). The relative expression of HOTTIP was calculated and normalized using the delta-delta CT (2−ΔΔCt) method relative to Beta-actin. Independent experiments were done in triplicate.

Statistical analysis

All these HRs and 95% CI were calculated following Tierney's method and the logHR and standard error (logHR) were used for aggregation of the survival results. Generally, an observed HR of >1 implied worse survival for the group with HOTTIP overexpression. This impact of high expression of HOTTIP on the survival rate was considered statistically significant if the 95% CI for the overall HR did not overlap in the forest plot. A test of heterogeneity of combined HRs was carried out using Cochran's Q test and Higgins I-squared statistic. Heterogeneity was defined as p<0.10 or I2>50%. Pooled HR was calculated using a fixed effect model or random effect model to evaluate the relationship between HOTTIP expression and overall survival. When homogeneity was fine (p>0.10, I2<50%), a fixed effect model was used for secondary analysis. If not, a random effect model was used. Publication bias was evaluated using the funnel plot and Egger's test, P>0.05 was considered indicative of a lack of publication bias. Using the Kaplan–Meier method, OS and DFS curves were made, and the log-rank test was applied for comparison. The significance of between-group differences was estimated using Student's t-test, χ2 test or Wilcoxon test, as appropriate. Variables with a value of P<0.05 in univariate analysis were used in a subsequent multivariate analysis, based on the Cox proportional hazards model. All P values were two-sided, and all analyses were performed using the Stata soft-ware (StataCorp, College Station, TX, USA) and Review Manager (v5.0; Oxford, United Kingdom).
  34 in total

1.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

2.  Long noncoding RNA as modular scaffold of histone modification complexes.

Authors:  Miao-Chih Tsai; Ohad Manor; Yue Wan; Nima Mosammaparast; Jordon K Wang; Fei Lan; Yang Shi; Eran Segal; Howard Y Chang
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

3.  A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression.

Authors:  Kevin C Wang; Yul W Yang; Bo Liu; Amartya Sanyal; Ryan Corces-Zimmerman; Yong Chen; Bryan R Lajoie; Angeline Protacio; Ryan A Flynn; Rajnish A Gupta; Joanna Wysocka; Ming Lei; Job Dekker; Jill A Helms; Howard Y Chang
Journal:  Nature       Date:  2011-03-20       Impact factor: 49.962

4.  Long noncoding RNA HOTTIP contributes to the progression of prostate cancer by regulating HOXA13.

Authors:  S-R Zhang; J-K Yang; J-K Xie; L-C Zhao
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2016-03-31       Impact factor: 1.770

Review 5.  The hallmarks of cancer: a long non-coding RNA point of view.

Authors:  Tony Gutschner; Sven Diederichs
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

6.  Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes.

Authors:  Xiaoping Su; Gabriel G Malouf; Yunxin Chen; Jianping Zhang; Hui Yao; Vicente Valero; John N Weinstein; Jean-Philippe Spano; Funda Meric-Bernstam; David Khayat; Francisco J Esteva
Journal:  Oncotarget       Date:  2014-10-30

7.  Over-expression of the long non-coding RNA HOTTIP inhibits glioma cell growth by BRE.

Authors:  Li-Min Xu; Lei Chen; Feng Li; Run Zhang; Zong-Yang Li; Fan-Fan Chen; Xiao-Dan Jiang
Journal:  J Exp Clin Cancer Res       Date:  2016-10-12

8.  The long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferation, survival and migration.

Authors:  Yating Cheng; Indira Jutooru; Gayathri Chadalapaka; J Christopher Corton; Stephen Safe
Journal:  Oncotarget       Date:  2015-05-10

9.  Long Noncoding RNAs in Interaction With RNA Binding Proteins in Hepatocellular Carcinoma.

Authors:  Ashraf Mohamadkhani
Journal:  Hepat Mon       Date:  2014-05-05       Impact factor: 0.660

10.  Oncogenic function of the homeobox A13-long noncoding RNA HOTTIP-insulin growth factor-binding protein 3 axis in human gastric cancer.

Authors:  Sophie Sw Wang; Kenly Wuputra; Chung-Jung Liu; Yin-Chu Lin; Yi-Ting Chen; Chee-Yin Chai; Chen-Lung Steve Lin; Kung-Kai Kuo; Ming-Ho Tsai; Shin-Wei Wang; Ker-Kong Chen; Hiroyuki Miyoshi; Yukio Nakamura; Shigeo Saito; Tadashi Hanafusa; Deng-Chyang Wu; Chang-Shen Lin; Kazunari K Yokoyama
Journal:  Oncotarget       Date:  2016-06-14
View more
  15 in total

1.  Long non-coding RNA BRAF-regulated lncRNA 1 promotes lymph node invasion, metastasis and proliferation, and predicts poor prognosis in breast cancer.

Authors:  Jing Jiang; Sheng-Hong Shi; Xu-Jun Li; Long Sun; Qi-Dong Ge; Chao Li; Wei Zhang
Journal:  Oncol Lett       Date:  2018-04-17       Impact factor: 2.967

2.  Long noncoding RNA LINC00963 promotes breast cancer progression by functioning as a molecular sponge for microRNA-625 and thereby upregulating HMGA1.

Authors:  Zhen Wu; Wei Wang; Yongkun Wang; Xin Wang; Shanping Sun; Yumin Yao; Yang Zhang; Zhongxi Ren
Journal:  Cell Cycle       Date:  2020-02-13       Impact factor: 4.534

3.  Long noncoding RNA lncHERG promotes cell proliferation, migration and invasion in glioblastoma.

Authors:  Jian Shi; Yong-Jie Wang; Chong-Ran Sun; Bin Qin; Yang Zhang; Gao Chen
Journal:  Oncotarget       Date:  2017-11-14

4.  The Impact of lncRNA Dysregulation on Clinicopathology and Survival of Breast Cancer: A Systematic Review and Meta-analysis.

Authors:  Tian Tian; Meng Wang; Shuai Lin; Yan Guo; Zhiming Dai; Kang Liu; Pengtao Yang; Cong Dai; Yuyao Zhu; Yi Zheng; Peng Xu; Wenge Zhu; Zhijun Dai
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-03       Impact factor: 8.886

5.  Long non‑coding RNA HOTTIP promotes hepatocellular carcinoma tumorigenesis and development: A comprehensive investigation based on bioinformatics, qRT‑PCR and meta‑analysis of 393 cases.

Authors:  Yu Zhang; Jia-Cheng Huang; Kai-Teng Cai; Xi-Bing Yu; You-Rong Chen; Wen-Ya Pan; Ze-Liang He; Jun Lv; Zhen-Bo Feng; Gang Chen
Journal:  Int J Oncol       Date:  2017-10-16       Impact factor: 5.650

6.  Prognostic value of the long noncoding RNA HOTTIP in human cancers.

Authors:  Wei Li; Na Li; Xinmei Kang; Ke Shi; Qiong Chen
Journal:  Oncotarget       Date:  2017-07-11

Review 7.  Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer.

Authors:  Samarth Kansara; Vijay Pandey; Peter E Lobie; Gautam Sethi; Manoj Garg; Amit Kumar Pandey
Journal:  Cells       Date:  2020-06-21       Impact factor: 6.600

8.  The Influence of rs1859168 Polymorphism on Serum Expression of HOTTIP and Its Target miR-615-3p in Egyptian Patients with Breast Cancer.

Authors:  Omayma O Abdelaleem; Olfat G Shaker; Marwa N AbdelHafez; Noha K Abdelghaffar; Hanaa M Eid; Mohamed Zaidan; Abeer A Khalefa; Naglaa A Ahmed; Nada F Hemeda; Othman M Zaki; Aeshah Ali A Awaji; Shereen R Mohammed
Journal:  Biomolecules       Date:  2021-05-14

9.  Knockdown of MALAT1 expression inhibits HUVEC proliferation by upregulation of miR-320a and downregulation of FOXM1 expression.

Authors:  Jian-Yong Sun; Zheng-Wei Zhao; Wei-Miao Li; Guang Yang; Peng-Yu Jing; Pei Li; Hai-Zhou Dang; Zhao Chen; Yong-An Zhou; Xiao-Fei Li
Journal:  Oncotarget       Date:  2017-06-16

10.  LncRNA HOTTIP-Mediated HOXA11 Expression Promotes Cell Growth, Migration and Inhibits Cell Apoptosis in Breast Cancer.

Authors:  Yanqin Sun; Chao Zeng; Siyuan Gan; Hongmei Li; Ying Cheng; Dongjie Chen; Rujia Li; Wei Zhu
Journal:  Int J Mol Sci       Date:  2018-02-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.